Selected article for: "antihypertensive drug and ARB ACEi"

Author: Iwanski, Jessika; Kazmouz, Sobhi G.; Li, Shuaizhi; Stansfield, Ben; Salem, Tori T.; Perez-Miller, Samantha; Kazui, Toshinobu; Jena, Lipsa; Uhrlaub, Jennifer L.; Lick, Scott; Nikolich-Žugich, Janko; Konhilas, John P.; Gregorio, Carol C.; Khanna, May; Campos, Samuel K.; Churko, Jared M.
Title: Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells
  • Cord-id: kw7oduka
  • Document date: 2021_9_1
  • ID: kw7oduka
    Snippet: The pathogenicity of SARS-CoV-2 has been attributed to its ability to enter through the membrane-bound angiotensin-converting enzyme 2 (ACE2) receptor. Therefore, it has been heavily speculated that angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy may modulate SARS-CoV-2 infection. In this study, exposure of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) and primary endothelial cells (hECs) to SARS-CoV-2 identified significant difference
    Document: The pathogenicity of SARS-CoV-2 has been attributed to its ability to enter through the membrane-bound angiotensin-converting enzyme 2 (ACE2) receptor. Therefore, it has been heavily speculated that angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy may modulate SARS-CoV-2 infection. In this study, exposure of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) and primary endothelial cells (hECs) to SARS-CoV-2 identified significant differences in protein coding genes involved in immunity, viral response, and cardiomyocyte/endothelial structure. Specifically, transcriptome changes were identified in the TNF, Interferon α/β, and MAPK (hPSC-CMs) as well as NF-kappaB (hECs) signalling pathways. However, pre-treatment of hPSC-CMs or hECs with two widely prescribed antihypertensive medications, losartan and lisinopril, did not affect the susceptibility of either cell type to SARS-CoV-2 infection. These findings demonstrate the toxic effects of SARS-CoV-2 in hPSC-CMs/hECs and taken together with newly emerging multicenter trials, suggest that antihypertensive drug treatment alone does not alter SARS-CoV-2 infection.

    Search related documents:
    Co phrase search for related documents
    • abundant protein and acute respiratory distress syndrome: 1, 2, 3
    • ace active site and active site: 1, 2, 3
    • acei arb treatment and acute respiratory distress syndrome: 1
    • acei enzyme inhibitor and acute kidney injury: 1
    • acei enzyme inhibitor and acute respiratory distress syndrome: 1
    • active metabolite and acute kidney injury: 1
    • active metabolite and acute respiratory distress syndrome: 1, 2, 3
    • active site and acute respiratory distress syndrome: 1, 2